Location of Repository

The role of PML proteins in adenovirus type 5 infection and the type I interferon response

By Jordan Wright

Abstract

Promyelocytic leukaemia (PML) proteins consist of a collection of related isoforms\ud that are the nucleating components of sub-nuclear structures termed PML nuclear\ud bodies (PML NBs). Numerous functions are attributed to PML and PML NBs,\ud including a role in antiviral responses. Adenovirus type 5 (Ad5) has previously been\ud shown both to disrupt PML NBs and to cause the appearance of a novel PML protein\ud species, termed PML-A, in a manner dependent on the viral E4 Orf3 protein. Here,\ud the interactions between Ad5 and PML proteins were further investigated.\ud The E4 Orf3-dependent species of PML (PML-A) was found to be related to the full-length\ud PML II isoform. In addition, two previously unknown infection-specific\ud species of PML were detected (PML-B and PML-C). Both PML-B and PML-C\ud were produced independently of Ad5 E4 Orf3, though their appearance required viral\ud DNA replication. PML-C was found to be localised within the cytoplasm of infected\ud cells and to be related to PML I.\ud To test the hypothesis that these changes in PML were related to virus effects on\ud antiviral responses, the roles of individual PML proteins in type I interferon (IFN)\ud signalling were investigated. Depletion of PML II by siRNA resulted in a 50%\ud decrease in activity of an IFNβ promoter reporter plasmid during stimulation by poly\ud (I:C). Exogenous expression of a ΔRBCC truncated mutant, but not full-length,\ud PML II resulted in enhanced IFNβ promoter activity, suggesting a role of a PML II-related\ud species in type I IFN signalling. Moreover, expression of the Ad5 E4 Orf3\ud protein was sufficient to inhibit the activity of the IFNβ promoter, an activity that\ud correlated with Orf3’s ability to bind PML II. Collectively, these data indicate that a\ud PML II-related molecule is involved in the interferon response and that the E4 Orf3-\ud PML II interaction may therefore facilitate Ad5 in mitigating this activity

Topics: QR, RC
OAI identifier: oai:wrap.warwick.ac.uk:3828

Suggested articles

Preview

Citations

  1. (2006). A CK2-Dependent Mechanism for Degradation of the PML Tumor Suppressor. doi
  2. (2006). A cytoplasmic PML mutant inhibits p53 function. doi
  3. (2010). A manually curated network of the PML nuclear body interactome reveals an important role for PML-NBs in SUMOylation dynamics. doi
  4. (1992). A monoclonal antibody recognizing nuclear matrix-associated nuclear bodies.
  5. (2008). A Role for Cytoplasmic PML in Cellular Resistance to Viral Infection. doi
  6. (2005). A Role for PML3 in Centrosome Duplication and Genome Stability. doi
  7. (2008). Acetylation of PML Is Involved in Histone Deacetylase Inhibitor-mediated Apoptosis. doi
  8. (1996). Adenoviridae: The Virues and Their Replication. Fields Virology,
  9. (1996). Adenovirus E4 open reading frame 4 protein autoregulates E4 transcription by inhibiting E1A transactivation of the E4 promoter. doi
  10. (1989). Adenovirus early region 4 encodes two gene products with redundant effects in lytic infection.
  11. (2004). Adenovirus endocytosis. doi
  12. (1996). Adenovirus replication is coupled with the dynamic properties of the PML nuclear structure. doi
  13. (2009). Adenovirus Serotype 5 L4-22K and L4-33K Proteins Have Distinct Functions in Regulating Late Gene Expression. doi
  14. (1998). Adenovirus Type 5 E4 Open Reading Frame 4 Protein Induces Apoptosis in Transformed Cells.
  15. (2009). Adenoviruses: update on structure and function. doi
  16. (2003). Adeonvirus protein IX sequesters host-cell promyelocytic leukaemia protein and contributes to efficient viral replication. doi
  17. (2007). Antiviral Response. doi
  18. (2005). Association of caspase-2 with the promyelocytic leukamia protein nuclear bodies. doi
  19. (1987). At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. doi
  20. (1999). Cell cycle regulation of PML modification and ND10 composition.
  21. (1977). Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5. doi
  22. (1970). Characteristics of a human diploid cell designated MRC-5. doi
  23. (1991). Characterization of a zinc finger gene disrupted by the t(15;17) in acute promyelocytic leukemia. doi
  24. (2006). Characterization of Endogenous Human Promyelocytic Leukemia Isoforms.
  25. (1989). Characterization of the Adenovirus Proteinase: Development and Use of a Specific Peptide Assay. doi
  26. (2008). CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor. doi
  27. (1970). Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4. doi
  28. (1998). Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. doi
  29. (1995). Constitutive episomal expression of polypeptide IX (pIX) in a 293-based cell line complements the deficiency of pIX mutant adenovirus type 5.
  30. (1998). Covalent Modification of PML by the Sentrin Family of Ubiquitin-like Proteins. doi
  31. (2006). Cross Talk between PML and p53 during Poliovirus Infection: Implications for Antiviral Defense. doi
  32. (1987). Crystallization, enzymatic cleavage, and the polarity of adenovirus type 2 fiber. doi
  33. (1955). Culture Characteristics of Four Permanent Lines of Human Cancer Cells.
  34. (2002). Deconstructing PML-induced premature senescence. doi
  35. (2001). Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. doi
  36. (2009). Differential suppressive effect of promyelocytic leukemia protein on the replication of different subtypes/strains of influenza A virus. doi
  37. (2001). DNA viruses and viral proteins that interact with PML nuclear bodies. doi
  38. (2007). Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. doi
  39. Dynamics of component exchange at PML nuclear bodies. doi
  40. (1997). E4 gene function in adenovirus, adenovirus vector and adenoassociated virus infections.
  41. (1979). Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. doi
  42. (2002). Endogenous type I interferons as a defense against tumors. doi
  43. (2006). Evidence for a Role of the Cellular ND10 Protein PML in Mediating Intrinsic Immunity against Human Cytomegalovirus Infections. doi
  44. (2009). Expanding PML's functional repertoire through post-translational mechanisms. Frontiers in Bioscience, doi
  45. (1995). Expression of adenovirus type 5 E4 Orf2 protein during lytic infection. doi
  46. (2006). Factors influencing subcellular localization of the human papillomavirus L2 minor structural protein. doi
  47. (2007). Fields Virology, doi
  48. (2007). Functional interaction between PML and SATB1 regulates224 chromatin-loop architecture and transcription of the MHC class I locus. doi
  49. (2009). Herpes Simplex Virus Type 1 Regulatory Protein ICP0 Aids Infection in Cells with a Preinduced Interferon Response but Does Not Impede Interferon-Induced Gene Induction. doi
  50. (2009). Herpesvirus protein ICP27 switches PML isoform by altering mRNA splicing. doi
  51. (2004). HPV E6 proteins interact with specific PML isoforms and allow distinctions to be made between different POD structures. doi
  52. (1994). Human adenovirus encodes two proteins which have opposite effects on accumulation of alternatively spliced mRNAs.
  53. (1996). Human adenovirus type 9 E4 open reading frame 1 encodes a cytoplasmic transforming protein capable of increasing the oncogenicity of CREF cells.
  54. (2006). Human Cytomegalovirus (HCMV) UL82 Gene Product (pp71) Relieves hDaxx-Mediated Repression of HCMV Replication. doi
  55. (2005). Human Papillomavirus Oncoprotein E7 Targets the Promyelocytic Leukemia Protein and Circumvents Cellular Senescence via the Rb and p53 Tumor Suppressor Pathways. doi
  56. (2009). Human TRIM Gene Expression in Response to Interferons. PLoS ONE 4, e4894.217
  57. (2007). Identification of candidate alternative lengthening of telomeres genes by methionine restriction and RNA interference. doi
  58. (2004). Identified by High-Resolution Two-Dimensional Gel Electrophoresis. doi
  59. (2003). IFN[lambda]s mediate antiviral protection through a distinct class II cytokine receptor complex. doi
  60. (1997). IKK-1 and IKK-2: Cytokine-Activated I{kappa}B Kinases Essential for NF-B Activation. doi
  61. (2003). IL-28, IL-29 and their class II cytokine receptor IL-28R. doi
  62. (1973). In vitro cultivation of human tumours: establishment of cell lines derived from a series of solid tumours.
  63. (2006). Inactivating a Cellular Intrinsic Immune Defense Mediated by Daxx Is the Mechanism through Which the Human Cytomegalovirus pp71 Protein Stimulates Viral Immediate-Early Gene Expression. doi
  64. (2005). Inactivating intracellular antiviral responses during adenovirus infection. doi
  65. (2003). Inhibition and Degradation. doi
  66. (2003). Integration of interferon[alpha]/[beta] signalling to p53 responses in tumour suppression and antiviral defence. doi
  67. (2000). Interferon Coordinately Inhibits the Disruption of PML-Positive ND10 and Immediate-Early227 Gene Expression by Herpes Simplex Virus. doi
  68. (2006). Interferon signalling network in innate defence. doi
  69. (2004). Interferons [alpha] and [gamma] induce p53-dependent and p53-independent apoptosis, respectively. doi
  70. (2008). Interferons and viruses: an interplay between induction, signalling, antiviral responses and virus countermeasures. doi
  71. (1999). Interferons Regulate the Phenotype of Wild-type and Mutant Herpes Simplex Viruses In Vivo. doi
  72. (1997). Involvement of the rfp tripartite motif in protein-protein interactions and subcellular distribution.
  73. (2005). IRF-7 is the master regulator of type-I interferon-dependent immune responses. doi
  74. (2005). Isoforms of the promyelocytic leukemia protein differ in their effects on ND10 organization. doi
  75. (1978). Isolation of deletion and substitution mutants of adenovirus type 5. doi
  76. (2006). L4-33K, an Adenovirus-encoded Alternative RNA Splicing Factor. doi
  77. (2003). Localization of influenza virus proteins to nuclear dot 10 structures in influenza virus-infected cells. doi
  78. (2009). Mislocalization of the MRN complex prevents ATR signaling during adenovirus infection. doi
  79. Mitotic accumulations of PML protein contribute to the re-establishment of PML nuclear bodies in G1. doi
  80. (2008). Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. doi
  81. (1983). Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein. doi
  82. (2005). ND10 Components Relocate to Sites Associated with Herpes Simplex Virus Type 1 Nucleoprotein Complexes during Virus Infection. doi
  83. (2007). New insights into the cytoplasmic function of PML. doi
  84. (2008). New insights into the role of PML in tumour suppression. doi
  85. (2008). New insights into the role of the subnuclear structure ND10 for viral infection. doi
  86. (2007). NS1 Proteins of Avian Influenza A Viruses Can Act as Antagonists of the Human Alpha/Beta Interferon Response. doi
  87. (1998). Optimization of transient gene expression in mammalian cells and potential for scale-up using flow electroporation. doi
  88. (2006). Pathogen Recognition and Innate Immunity. doi
  89. (2006). PML Contributes to a Cellular Mechanism of Repression of Herpes Simplex Virus Type 1 Infection That Is Inactivated by ICP0. doi
  90. (2008). PML enhances the regulation of p53 by CK1 in response to DNA damage. doi
  91. (1999). Pml Is Critical for Nd10 Formation and Recruits the Pml-Interacting Protein Daxx to This Nuclear Structure When Modified by Sumo-1. doi
  92. (1998). Pml is essential for multiple apoptotic pathways. doi
  93. (2001). PML mediates the interferon-induced antiviral state against a complex retrovirus via its association with the viral transactivator. doi
  94. (2004). PML nuclear bodies: dynamic sensors of DNA damage and cellular stress. doi
  95. (2000). PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. doi
  96. (2004). PML regulates p53 stability by sequestering Mdm2 to the nucleolus. doi
  97. PML-IV functions as a negative regulator of telomerase by interacting with TERT. doi
  98. (2009). PML3 interacts with TRF1 and is essential for ALT-associated PML bodies assembly in U2OS cells. doi
  99. (2009). PML3 Orchestrates the Nuclear Dynamics and Function of TIP60. doi
  100. (2007). PML4 induces differentiation by Myc destabilization. doi
  101. (2006). Promyelocytic leukemia nuclear bodies behave as DNA damage sensors whose response to DNA double-strand breaks is regulated by NBS1 and the kinases ATM, Chk2, and ATR. doi
  102. (2001). Proteasome-Independent Disruption of PML Oncogenic Domains (PODs), but Not Covalent Modification by SUMO-1, Is Required for Human Cytomegalovirus Immediate-Early Protein IE1 To Inhibit PML-Mediated Transcriptional Repression. doi
  103. (2006). Rabies Viral Mechanisms to Escape the IFN System: The Viral Protein P Interferes with IRF-3, Stat1, and PML Nuclear Bodies. doi
  104. (2005). Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. doi
  105. (1998). Recruitment of CBP/p300 by the IFN[beta] Enhanceosome Is Required for Synergistic Activation of Transcription. doi
  106. (1998). Regulation of adenovirus alternative RNA splicing by dephosphorylation of SR proteins. doi
  107. (2000). Regulation of p53 activity in nuclear bodies by a specific PML isoform.
  108. (1979). Regulation of the Interferon System: Evidence that Vero Cells have a Genetic Defect in Interferon Production. doi
  109. Resistance to Virus Infection Conferred by the Interferon-Induced Promyelocytic Leukemia Protein.
  110. (2009). RIG-I-dependent sensing of poly(dA:dT) through the induction of an RNA polymerase III-transcribed RNA intermediate. doi
  111. (2008). RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation. doi
  112. (2006). Role for Centromeric Heterochromatin and PML Nuclear Bodies in the Cellular Response to Foreign DNA. doi
  113. (2008). Role of nuclear bodies in apoptosis signalling. doi
  114. (2005). Serum-dependent expression of promyelocytic leukemia protein suppresses propagation of influenza virus. doi
  115. (2008). STAT-1- and IRF-3-Dependent Pathways Are Not Essential for Repression of ICP0-Null Mutant Herpes Simplex Virus Type 1 in Human Fibroblasts. doi
  116. (2007). Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. doi
  117. (2004). SUMO and ubiquitin in the nucleus: different functions, similar mechanisms? doi
  118. (2008). SUMO Conjugation to the Matrix Attachment Region-binding Protein, doi
  119. (1999). SUMO-1 modification of the acute promyelocytic leukaemia protein PML: implications for nuclear localisation.
  120. (2004). SUMO: a regulator of gene expression and genome integrity. doi
  121. (1995). The acute promyelocytic leukaemiaassociated PML gene is induced by interferon.
  122. (1999). The adenovirus type 5 E1b 55K and E4 Orf3 proteins associate in infected cells and affect ND10 components.
  123. (1994). The beta-interferon promoter responds to priming through multiple independent regulatory elements.
  124. (2007). The control of viral infection by tripartite motif proteins and cyclophilin A. doi
  125. (2004). The Herpes Simplex Virus ICP0 RING Finger Domain Inhibits IRF3- and IRF7-Mediated Activation of Interferon-Stimulated Genes. doi
  126. (2006). The interferon response circuit: Induction and suppression by pathogenic viruses. doi
  127. (2002). The interferon-[alpha]/[beta] system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. doi
  128. (2006). The Mechanisms of PML-Nuclear Body Formation. doi
  129. (2006). The number of PML nuclear bodies increases in early S phase by a fission mechanism. doi
  130. (1997). The product of the adenovirus intermediate gene IX is a transcriptional activator.
  131. (2006). The promyelocytic leukemia protein functions as a negative regulator of IFN-{gamma} signaling. doi
  132. The promyelocytic leukemia protein stimulates SUMO conjugation in yeast. doi
  133. (2001). The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E. doi
  134. (1999). The role of HMG I(Y) in the assembly and function of the IFN-[beta] enhanceosome. doi
  135. (1996). The role of the adenovirus protease on virus entry into cells. doi
  136. (1990). The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor [alpha] gene to a novel transcribed locus. doi
  137. (2001). The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. doi
  138. (2010). Threedimensional organization of promyelocytic leukemia nuclear bodies. doi
  139. (1998). to the Cytoplasm.
  140. (2009). Toll-like receptors and innate immunity. doi
  141. (2008). TRIM family proteins and their emerging roles in innate immunity. doi
  142. (2005). TRIM family proteins: retroviral restriction and antiviral defence. doi
  143. (1993). Two Adenovirus Proteins with Redundant Activities doi
  144. (1967). Two established in vitro cell lines from human mesenchymal tumours. doi
  145. (2006). Type I Inteferon Gene Induction by the Interferon Regulatory Factor Family of Transcription Factors. doi
  146. (2008). Type I interferon-dependent and -independent expression of tripartite motif proteins in immune cells. doi
  147. (2006). Type I Interferons in Host Defense. doi
  148. (2000). Ubiquitination: RING for destruction? doi
  149. (2000). Update on adenovirus and its vectors.
  150. (1995). Virus induction of human IFN[beta] gene expression requires the assembly of an enhanceosome. doi
  151. (2006). Viruses and the Nucleus, 1st edn, pp. Chapter 8: Virus Interactions with PML Nuclear Bodies. Edited by

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.